Gnas Inactivation Alters Subcutaneous Tissues in Progression to Heterotopic Ossification.
Brewer N., Fong JT., Zhang D., Ramaswamy G., Shore EM.
Laboratory Study, published in Front Genet (2021) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Front Genet (2021)
- Country
- Switzerland
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 33574833
- PMCID
- PMC7870717
- DOI
- 10.3389/fgene.2021.633206
- Citations
- 6
Abstract (original English)
Heterotopic ossification (HO), the formation of bone outside of the skeleton, occurs in response to severe trauma and in rare genetic diseases such as progressive osseous heteroplasia (POH). In POH, which is caused by inactivation of GNAS , a gene that encodes the alpha stimulatory subunit of G proteins (Gsα), HO typically initiates within subcutaneous soft tissues before progressing to deeper connective tissues. To mimic POH, we used conditional Gnas -null mice which form HO in subcutaneous tissues upon Gnas inactivation. In response to Gnas inactivation, we determined that prior to detection of heterotopic bone, dermal adipose tissue changed dramatically, with progressively decreased adipose tissue volume and increased density of extracellular matrix over time. Upon depletion of the adipose tissue, heterotopic bone progressively formed in those locations. To investigate the potential relevance of the tissue microenvironment for HO formation, we implanted Gnas -null or control mesenchymal progenitor cells into Gnas -null or control host subcutaneous tissues. We found that mutant cells in a Gnas -null tissue environment induced a robust HO response while little/no HO was detected in control hosts. Additionally, a Gnas -null tissue environment appeared to support the recruitment of control cells to heterotopic bone, although control cell implants were associated with less HO for
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.